$T2 Biosystems (TTOO.US)$
T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year.
Sepsis test panel revenue reached $1.4 million, also increasing 34%.
The company secured 11 T2Dx® Instrument contracts and initiated an exclusive U.S. distribution agreement with Cardinal Health.
Net loss was $10.1 million ($0.57 per share), improving from $15.4 million loss in Q3 2023.
Cash position stood at $2.1 million as of September 30...

$NextTrip (NTRP.US)$
NextTrip Plans to Acquire Luxury Travel Company Five Star Alliance

$T2 Biosystems (TTOO.US)$ bravo

$T2 Biosystems (TTOO.US)$ T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

$T2 Biosystems (TTOO.US)$
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

$T2 Biosystems (TTOO.US)$ Chinese BQ stock up 35% last week . today up15% high now back 8%